Rchr
J-GLOBAL ID：201501018673483456
Update date: Feb. 03, 2024
Terakawa Tomoaki
テラカワ トモアキ | Terakawa Tomoaki
Affiliation and department：
Job title：
Assistant Professor
Research field (1)：
Urology
Research theme for competitive and other funds (2)：
- 2011 - 腎細胞癌におけるAurora-Aの役割の解明および新規治療の開発
- 2010 - 前立腺癌のホルモン非依存性進展におけるInterleukin-6の役割の解明
Papers (202)：
-
Takuto Hara, Junya Furukawa, Takahiro Tsutiya, Takayuki Kodama, Keiichiro Uehara, Tomoaki Terakawa, Kenichi Harada, Jun Teishima, Yuzo Nakano, Masato Fujisawa. Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: A case of pathological complete response with pembrolizumab plus lenvatinib. IJU case reports. 2024. 7. 1. 60-63
-
Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, et al. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model. Scientific reports. 2023. 13. 1. 9994-9994
-
Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Junichiro Hirata, Naoe Jimbo, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, et al. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer. Japanese journal of clinical oncology. 2023. 53. 6. 522-529
-
Hideaki Miyake, Yasumasa Kakei, Yuzo Nakano, Tomoaki Terakawa, Keiko Miyakoda, Kenichi Harada, Masato Fujisawa. Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial. BMJ Open. 2023. 13. 3. e070173
-
Naoto Wakita, Nobuyuki Hinata, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer research. 2023. 43. 2. 841-847
ｍore...
MISC (156)：
-
Tomoaki Terakawa, Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa. Clinical outcome of EP therapy (VP16+CDDP)in 10 prostate cancer patients with neuroendocrine differentiation. INTERNATIONAL JOURNAL OF UROLOGY. 2020. 27. 74-75
-
Yukari Bando, Nobuyuki Hinata, Yusuke Shiraishi, Naoto Wakita, Mariko Sakamoto, Yasuyoshi Okamura, Kotaro Yuzuki, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, et al. PREDICTIVE EFFICACYOF SERUMSOLUBLE PD-L1ONPATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB. JOURNAL OF UROLOGY. 2020. 203. E239-E240
-
原琢人, 白石祐介, 脇田直人, 坂本茉莉子, 岡村泰義, 板東由加里, 鈴木光太郎, 寺川智章, 古川順也, 原田健一, et al. 当院における腎癌患者のニボルマブとイピリムマブ併用療法の治療成績. 西日本泌尿器科. 2020. 82
-
寺川 智章, 白石 祐介, 脇田 直人, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, et al. 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌10例の臨床的検討. 西日本泌尿器科. 2019. 81. 増刊. 173-173
-
寺川 智章, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, et al. 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌10例の臨床的検討. 日本癌治療学会学術集会抄録集. 2019. 57回. P103-7
ｍore...
Lectures and oral presentations (163)：
-
Treatment outcomes of non-metastatic castration-resistant prostate cancer
(2020)
-
Clinical outcome of EP therapy (VP16+CDDP)in 12 prostate cancer patients with neuroendocrine differentiation
(2020)
-
Presurgical therapyによって腎静脈内まで腫瘍塞栓が縮小し腹腔鏡下に摘除し得た腎癌下大静脈腫瘍塞栓の1例
(第70回 日本泌尿器科学会中部総会 2020)
-
Clinical outcome of EP therapy (VP16+CDDP)in 10 prostate cancer patients with neuroendocrine differentiation
(2020)
-
腎盂尿管移行部狭窄症に対するロボット支援腹腔鏡下腎盂形成術の初期経験
(第33回日本泌尿器内視鏡学会 2019)
ｍore...
Education (1)：
- - 2010 神戸大学 大学院医学系研究科博士課程医科学専攻修了
Professional career (1)：
Return to Previous Page
